Phaseline

Companies › Teclison

Teclison: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Trans-arterial tirapazamine embolization (TATE)
Hypoxia-activated prodrug embolized intra-arterially to deliver tirapazamine to liver tumo
TPZMPhase 2Hepatocellular CarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03259867Trans-arterial tirapazamine embolization (TATE)Phase 2Hepatocellular CarcinomaOncologyDec 2026
NCT02174549Trans-arterial tirapazamine embolization (TATE)Phase 1Hepatocellular CarcinomaOncologyMar 2028

Targets

TPZM (1)

Companies with the same targets

–

Companies built like this

iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.